Sygnature Discovery, a global integrated drug discovery company and Daewoong Pharmaceutical, a global healthcare group, entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease. Sygnature Discovery will provide integrated drug discovery support using specialist fragment-based drug discovery (FBDD) and virtual high throughput screening (vHTS) expertise from its medicinal chemistry, biology, and computational science team...